Status:
RECRUITING
Curcumin Supplementation in Cervical Cancer
Lead Sponsor:
National Institute of Cancerología
Collaborating Sponsors:
Sabinsa Corporation
Conditions:
Locally Advanced Cervical Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Brief Summary. The goal of this pilot study is to learn about the effect of curcumin supplementation in locally advanced cervical cancer patients. The main questions it aims to answer are: * Does cu...
Detailed Description
BACKGROUND Cervical cancer (CC) continues to be a major public health problem in Mexico. Today more than 4,000 women die each year from this disease, which requires implementing strategies that can im...
Eligibility Criteria
Inclusion
- Understanding the nature of the study and giving a written consent report.
- Women \> 18 years old.
- ECOG performance status: 0-2.
- Be willing and able to comply with scheduled visits, treatment plans, and laboratory tests.
- Patients with a histological cervical cancer diagnosis: squamous cell, adenosquamous, adenocarcinoma, and glassy cell carcinoma.
- Classified with clinical stage IB3-IVA (FIGO 2018).
- Candidates to receive concomitant QT-RT followed by BT.
- With disease measurable by any imaging method (CT/MRI/PET-CT) according to RECIST v 1.1 criteria.
- Patients without prior treatment based on QT-RT.
- Hemoglobin ≥ 10 g/dL.
- Leukocytes ≥ 4000/mm3.
- Platelets ≥ 100,000/mm3.
- Adequate liver function.
Exclusion
- Patients undergoing nutritional treatment or ingesting any dietary supplement, including those containing turmeric or turmeric derivatives, ginger, or rhizome of the turmeric family.
- Patients with uncontrolled intercurrent diseases, including active infections that contraindicate CT.
- Patients receiving concomitant treatment with an experimental drug.
- Patients with vesicovaginal or vesicorectal fistula are diagnosed.
- Patients with previous or concomitant malignancy except non-melanoma skin carcinoma.
Key Trial Info
Start Date :
April 19 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06080841
Start Date
April 19 2023
End Date
March 1 2026
Last Update
May 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Cancerología
Mexico City, Mexico City, Mexico, 14080